| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.29B | 2.00B | 1.37B | 12.71M | 746.55M | 848.87M |
| Gross Profit | 313.85M | 218.68M | 43.64M | -263.37M | 48.35M | 74.10M |
| EBITDA | 104.98M | 16.85M | 4.69B | -469.06M | 785.63M | -1.39B |
| Net Income | 772.61M | 769.60M | 4.22B | -1.44B | -400.80M | -2.43B |
Balance Sheet | ||||||
| Total Assets | 4.69B | 4.54B | 5.21B | 5.85B | 6.48B | 7.60B |
| Cash, Cash Equivalents and Short-Term Investments | 221.55M | 85.47M | 315.41M | 41.77M | 109.13M | 153.32M |
| Total Debt | 3.60B | 3.69B | 5.45B | 8.91B | 8.44B | 8.96B |
| Total Liabilities | 6.89B | 6.50B | 9.25B | 13.64B | 13.18B | 13.62B |
| Stockholders Equity | -2.21B | -1.95B | -4.04B | -7.54B | -6.52B | -5.86B |
Cash Flow | ||||||
| Free Cash Flow | 64.48M | 76.04M | -94.24M | -94.19M | -501.02M | -43.02M |
| Operating Cash Flow | 67.68M | 76.04M | -50.46M | -88.01M | -475.21M | -26.19M |
| Investing Cash Flow | -3.74M | -535.00K | -14.37M | -413.00K | 392.59M | 120.09M |
| Financing Cash Flow | 29.89M | -76.06M | 112.62M | 109.75M | -48.66M | -25.87M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$1.02B | 8.55 | 5.08% | 10.12% | -1.19% | -9.05% | |
68 Neutral | HK$280.00M | 10.61 | 5.48% | 0.82% | 5.43% | -25.42% | |
65 Neutral | HK$1.16B | 2.57 | 10.38% | 5.10% | -6.58% | 16.23% | |
64 Neutral | HK$872.23M | -36.99 | -0.99% | 14.55% | -4.42% | -157.03% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | HK$59.36M | -0.45 | -28.48% | ― | 56.39% | -81.41% | |
44 Neutral | HK$1.36B | 0.94 | ― | ― | 42.14% | -81.25% |
Global Bio-chem Technology Group Co. Ltd. has successfully completed the issuance of Consideration Shares under a specific mandate and the conversion of Convertible Bonds. This strategic move, which involved the issuance of over 2.7 billion Consideration Shares and the conversion of bonds into over 5.1 billion shares, allows the company to fully capitalize its Suppliers Debt, making the Target Companies its wholly-owned subsidiaries. This restructuring is expected to enhance the company’s financial stability and operational efficiency.
Global Bio-chem Technology Group Co. Ltd. announced that an ordinary resolution was passed at their Extraordinary General Meeting (EGM), approving the Share Purchase Agreements (SPAs) and related transactions. The resolution included granting a Specific Mandate for the allotment and issuance of Consideration Shares, with unanimous support from shareholders. This decision reflects the company’s strategic direction and could potentially enhance its market position by facilitating new transactions and expansions.
Global Bio-chem Technology Group Co. Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a revenue increase to HK$1,185,983,000 from HK$898,541,000 in the same period of 2024. Despite the revenue growth, the company faced a total comprehensive loss of HK$251,895,000, attributed to high finance costs and other expenses, impacting its financial performance and indicating challenges in maintaining profitability.
Global Bio-chem Technology Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for September 18, 2025, in Hong Kong. The meeting aims to approve resolutions related to the company’s strategic plans, including the allotment and issuance of Consideration Shares under Specific Mandates. This move is expected to impact the company’s operational strategies and potentially influence its market positioning.
Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The circular, initially expected by 22 August 2025, will now be dispatched by 5 September 2025, as additional time is needed to finalize certain information. This delay may impact stakeholders awaiting detailed information on the debt restructuring and share issuance.
Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
Global Bio-chem Technology Group Co. Ltd. announced the successful closure of a public tender for an EPC Contract related to a Boiler Refurbishment Project. The contract, valued at a maximum of RMB129.1 million, was awarded to Northeast Electric and Liaoning Electric as joint bidders. This transaction is classified as a discloseable transaction under the Listing Rules due to its size, requiring notification and announcement. The project involves comprehensive engineering, procurement, and construction tasks, with incentives for early completion, potentially impacting the company’s operational efficiency and market positioning.
Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The delay is due to the need for additional time to prepare and finalize necessary information, with the new dispatch date set on or before August 22, 2025. This delay may impact the company’s operational timelines and stakeholder expectations, as the circular is crucial for informing shareholders about the upcoming Extraordinary General Meeting and related transactions.